Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Bausch Health Companies (BHC)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY – Research Report) and Bausch Health Companies (BHC – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eli Lilly & Co (LLY)
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1293.00. The company’s shares closed last Tuesday at $1042.15.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $1261.00, implying a 20.9% upside from current levels. In a report issued on February 19, Barclays also initiated coverage with a Buy rating on the stock with a $1350.00 price target.
See today’s best-performing stocks on TipRanks >>
Bausch Health Companies (BHC)
In a report released today, Glen Santangelo from Barclays maintained a Hold rating on Bausch Health Companies, with a price target of $7.00. The company’s shares closed last Tuesday at $6.02.
According to TipRanks.com, Santangelo is a 4-star analyst with an average return of
Currently, the analyst consensus on Bausch Health Companies is a Hold with an average price target of $7.25, which is a 20.8% upside from current levels. In a report issued on February 19, Truist Financial also maintained a Hold rating on the stock.
